| scholarly article | Q13442814 |
| P2093 | author name string | Satyajit Patra | |
| Vanesa Young | |||
| Jesil Mathew | |||
| Jitendra N Senapati | |||
| Leslie Llewellyn | |||
| P2860 | cites work | PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer | Q24338724 |
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications | Q27001729 | ||
| Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: implications for catalytic proton transfer and inhibitor design | Q27729300 | ||
| Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic | Q27824826 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. | Q27851582 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
| Trastuzumab emtansine: mechanisms of action and drug resistance | Q33759627 | ||
| Sequence analysis of mutations and translocations across breast cancer subtypes | Q34032470 | ||
| Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention | Q34103963 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
| HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development | Q34499609 | ||
| Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer | Q34664129 | ||
| Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients | Q35036895 | ||
| Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial | Q35419840 | ||
| The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review | Q36294151 | ||
| Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications | Q36986099 | ||
| Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer | Q37145885 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| Antibody-based therapy for solid tumors | Q37184302 | ||
| Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines | Q37263096 | ||
| ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. | Q37317337 | ||
| Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer | Q37317395 | ||
| Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. | Q37360367 | ||
| PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer | Q37380424 | ||
| Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). | Q37489864 | ||
| Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells | Q37690005 | ||
| Molecular determinants of trastuzumab efficacy: What is their clinical relevance? | Q38096651 | ||
| Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. | Q38238740 | ||
| Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer | Q38286163 | ||
| The role of p95HER2 in trastuzumab resistance in breast cancer | Q38379899 | ||
| Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab | Q39212216 | ||
| The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines | Q39669204 | ||
| Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. | Q39771406 | ||
| Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 | ||
| Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy | Q87177751 | ||
| P433 | issue | 8 | |
| P921 | main subject | trastuzumab | Q412616 |
| cancer cell line | Q23058136 | ||
| P304 | page(s) | 2209-2213 | |
| P577 | publication date | 2017-08-27 | |
| P1433 | published in | Asian Pacific Journal of Cancer Prevention | Q15759519 |
| P1476 | title | BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model | |
| P478 | volume | 18 |
Search more.